An apparent paradox is that whereas GLP-1 increases glucose-stimulated insulin secretion in the isolated pancreas fulfilling the definition of an incretin but it lowers insulin secretion in physiologically relevant conditions [6, 10, 18]
Those of us who want GLP-1s for metabolic balance or recovery support dont fit the criteria
Clinical trials show that patients average 2 to 5 pounds in the first 4 weeks of semaglutide therapy, depending on starting dose, adherence, and individual metabolism
However, even with these promising developments, the largely unregulated exploitative marketplace for selling GLP-1 products persists and now involves marketing personalized compounded GLP-1 weight-loss drugs, which can cause harm due to unknown formulations, dosing errors, and severe side effects
While the results demonstrate a striking difference favoring surgery, lead investigator Megan Jenkins, MD, a bariatric surgeon at NYU Langone Medical Center in New York City, emphasized that surgery and medication ought to be viewed not in opposition but through a holistic lens as options and potential complements based on the needs of each patient
, , , , , , 27 , 30
